CN112342288A - Application of biomarker for diagnosis - Google Patents

Application of biomarker for diagnosis Download PDF

Info

Publication number
CN112342288A
CN112342288A CN202010989515.4A CN202010989515A CN112342288A CN 112342288 A CN112342288 A CN 112342288A CN 202010989515 A CN202010989515 A CN 202010989515A CN 112342288 A CN112342288 A CN 112342288A
Authority
CN
China
Prior art keywords
mir
biomarker
polycystic ovarian
ovarian syndrome
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN202010989515.4A
Other languages
Chinese (zh)
Inventor
李向东
张珊珊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN202010989515.4A priority Critical patent/CN112342288A/en
Publication of CN112342288A publication Critical patent/CN112342288A/en
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Abstract

The invention provides a miRNA biomarker for diagnosis of polycystic ovarian syndrome, wherein the miRNA biomarker is miR-615-5 p. The invention detects the expression of miR-615-5p in parietal granulosa cells, cumulus granulosa cells and serum of PCOS patients and healthy controls, and finds that the miR-615-5p level is obviously reduced. Overexpression of miR-615-5p in human primary granulosa cells and human ovarian granulosa cell line KGN promotes granulosa cell proliferation and estrogen production. DHT (dihydrotestosterone) is adopted to induce a mouse polycystic ovarian syndrome mouse model, and miR-615-5p is found to be low in expression in the ovary of the mouse model of polycystic ovarian syndrome. The research shows that miR-615-5p can be used as a biomarker of polycystic ovarian syndrome and provides a theoretical basis for clinical pharmacy.

Description

Application of biomarker for diagnosis
Technical Field
The present invention relates to the fields of molecular biology and disease gene research and diagnosis. Specifically, the invention relates to a microRNA biomarker of polycystic ovarian syndrome (PCOS) and application of the microRNA in preparation of a kit or a gene chip for diagnosing or detecting the polycystic ovarian syndrome.
Background
Polycystic ovary syndrome (PCOS) affects 6-8% of women of reproductive age, one of the most common endocrine disorders. The most common clinical manifestations of the disease are hyperandrogenism in women, resulting in menstrual disorders, rarity, amenorrhea or irregular vaginal bleeding, infertility, obesity, hirsutism, endometrial hyperproliferation and malignant changes, and polycystic changes in bilateral or unilateral ovaries with a high incidence of the obese phenotype; insulin resistance occurs in the endocrine metabolism of glycolipid, which leads to complications such as diabetes, and long-term complications also include cardiovascular diseases, endometrial cancer and the like. The clinical manifestations of PCOS are heterogeneous, and the research on the relevant mechanisms of the disease has been a hotspot and difficulty in the basic research. Thus, a further understanding of the molecular mechanisms underlying PCOS pathophysiology may help identify new diagnostic and therapeutic targets.
miRNA is small non-coding RNA with the endogenous length of about 21-25nt, and plays an important role in regulating and controlling the degradation and inhibition of target gene mRNA. mirnas, as biomarkers of potential tissue-specific diseases, can provide effective measures for many pathological diagnoses. Abnormal expression of miRNAs is associated with several metabolic disorders (including obesity, diabetes, PCOS, etc.), and several studies have highlighted the function of miRNAs to maintain metabolic homeostasis. Thus, mirnas are potential regulators of metabolic processes and are promising targets for the regulation of PCOS and related disease-related complex pathways.
Disclosure of Invention
The present invention provides miRNA biomarkers indicative of polycystic ovary syndrome (PCOS). The present invention provides methods for detecting or diagnosing PCOS by detecting changes in the expression levels of mirnas of the biomarkers in a sample, particularly a granulosa cell sample, and kits or gene chips for use in these methods.
The miRNA biomarker for diagnosis of polycystic ovarian syndrome provided by the invention is miR-615-5 p. The mature sequence is as follows: GGGGGUCCCCGGUGCUCGGAUC are provided.
The invention also provides application of the miR-615-5p in preparation or screening of a diagnosis and treatment medicament for the human polycystic ovary syndrome.
The invention also provides application of the miR-615-5p in preparation of a human polycystic ovary syndrome detection reagent. The detection reagent is selected from related reagents for detecting the biomarker miR-615-5p by methods such as southern blotting, northern blotting, PCR (polymerase chain reaction), reverse transcriptase PCR (polymerase chain reaction), real-time quantitative PCR (polymerase chain reaction), nano-array method, macro-array method, autoradiography or in-situ hybridization.
The invention further provides a kit for diagnosing polycystic ovarian syndrome, which comprises one or more primers and/or probes for specifically detecting the expression level of miR-615-5 p.
The primer is designed based on the real-time quantitative PCR method for detecting miR-615-5p, and the primer sequence is as follows:
miR-615-5p-RT:5’-GTCGTATCCAGTGCAGGGTCCGAGGTGCACTGGATACGACCATCCGA-3’
miR-615-5p-F:5’-TGCACGGGGGTCCCCGGTGCTCG-3’
miR-615-5p-R:5’-CTCAACTGGTGTCGTGGAGTC-3’
mirnas are widely expressed in female reproductive tract ovaries, uterus, endometrium, oviducts, and during embryonic development, and by specifically binding to their target genes, cause degradation of the target mRNA or inhibit its translation. The research on miRNA perfects and enriches the molecular biology and genetics mechanism of disease occurrence and development. Research shows that the over-expression of miR-615-5p promotes the proliferation of granulosa cells and the generation of estrogen. The low expression of miR-615-5p in granulosa cells causes the dyssecretion of estrogen and androgen in follicular membranes of the granulosa cells, and causes polycystic ovary syndrome.
The invention detects the expression of miR-615-5p in parietal granulosa cells, cumulus granulosa cells and serum of PCOS patients and normal people, and finds that the miR-615-5p level is obviously reduced. The over-expression of miR-615-5p in the granular cells promotes the proliferation of the granular cells and the production of estrogen. DHT (dihydrotestosterone) is adopted to induce a mouse polycystic ovarian syndrome model, and miR-615-5p is found to be low in expression in the ovary of the mouse of the polycystic ovarian syndrome model. miR-615-5p can be used as a biomarker of polycystic ovarian syndrome, and provides a theoretical basis for clinical pharmacy.
Drawings
Fig. 1 is a graph showing the expression of miR-615-5p in parietal granulosa cells from healthy controls (n-8), PCOS patients (n-15), in example 1 of the present invention.
Fig. 2 is a graph showing the expression of miR-615-5p in cumulus granular cells from healthy controls (n-16), PCOS patients (n-17) in example 1 of the present invention.
Fig. 3 is a graph showing the expression of miR-615-5p in the serum from healthy controls (n-17), PCOS patients (n-16) in example 1 of the present invention.
FIG. 4 shows that miR-615-5p overexpression promotes the production of human primary granulosa cell (hGC) estrogen in example 2 of the present invention.
FIG. 5 shows that miR-615-5p overexpression promotes estrogen secretion in KGN cell line in example 2 of the present invention.
FIG. 6 shows that the ovaries of the offspring adult female mice of the PCOS model group, i.e., DHT-treated group, in example 3 of the present invention exhibit a polycystic shape.
FIG. 7 shows that the expression level of miR-615-5p in ovary of polycystic ovary syndrome model mouse in example 3 of the invention is remarkably reduced.
Detailed Description
The following examples are intended to illustrate the invention but are not intended to limit the scope of the invention. Unless otherwise specified, the technical means used in the examples are conventional means well known to those skilled in the art, and the raw materials used are commercially available products.
Example 1 application of miR-615-5p as miRNA biomarker for diagnosis of polycystic ovarian syndrome
The expression of miR-615-5p in human granulosa cells was quantitatively analyzed by RNA extraction, reverse transcription and real-time (RT) -PCR.
1. Total RNA was extracted from human granulosa cells using standard extraction protocols based on TRIzol, quantitated using a NanoDrop1000 spectrophotometer, and stored at-80 ℃ if not used immediately, according to the manufacturer's instructions.
2. RT was performed using a complementary DNA synthesis kit (Thermo Fisher Scientific) under the following conditions: 42 ℃ for 90 minutes, 95 ℃ for 5 minutes, held at 4 ℃. Reverse transcription of miRNA is performed using a Stem-loop RT-Primer specific for miRNA as a Primer. The internal reference is small nuclear RNA U6. The reverse transcription primer for U6 was 5'-AACGCTTCACGAATTTGCGT-3'. The reverse primer of miR-615-5p is 5'-GTCGTATCCAGTGCAGGGTCCGAGGTGCACTGGATACGACCATCCGA-3'.
3. Complementary DNA was amplified in a Roche LightCycler 480 system using SYBR Green Master Mix Reagent (Roche, Switzerland). The cycling conditions were as follows: denaturation at 95 ℃ for 10 min, then at 95 ℃ for 10 sec, at 60 ℃ for 10 sec, and at 72 ℃ for 10 cycles of 40 cycles. The amplification primers were as follows:
U6-F:5’-CTCGCTTCGGCAGCACA-3’；
U6-R:5’-AACGCTTCACGAATTTGCGT-3’；
miR-615-5p-F:5’-TGCACGGGGGTCCCCGGTGCTCG-3’；
miR-615-5p-R:5’-CTCAACTGGTGTCGTGGAGTC-3’
the data obtained were analyzed using 480software, Version 1.5.
The analysis result shows that the expression of miR-615-5p in parietal granulosa cells, cumulus granulosa cells and serum of the PCOS patient is remarkably increased compared with that of a control group (figures 1 to 3).
Example 2 Effect of miR-615-5p on the promotion of steroid production
Human primary granular cells (hCG) and a human ovarian granular cell line (KGN) are cultured in vitro and divided into a miR-615-5p group and a control group, miR-615-5p (namely miR-615-5p imic, GGGGGUCCCCGGUGCUCGGAUC) and miR-NC are transfected respectively, and the change of the estrogen content in cell supernatant is detected.
1. Effect of miR-615-5p on estradiol secretion by granulosa cells
(1) Cell transfection
Lipofectamine manufactured by Invitrogen corporation was usedTM2000, operating as per the instructions (taking 6-well plates, A, B in total, one well for each group, 3 multiple wells for each treatment group at the time of actual transfection):
cells were seeded 24 hours before transfection (4X 10)5One/well), cultured in serum-containing medium, the cell adherence rate is about 70% -80% after 24 hours; changing a serum-free culture medium 2 hours before transfection; transfection was performed in the following A, B two groups, group C being diluted transfection reagent.
A: 100pmol miR-NC mici (mimic) + 250. mu.L serum-free DMEM/F12 medium
B: 100pmol miR-615-5p micic (mimic) +250 uL serum-free DMEM/F12 medium
C：5μL LipofectamineTM2000+ 250. mu.L serum-free DMEM/F12 medium
The two groups of premixed liquid are prepared, blown, beaten and uniformly mixed, and are kept stand for 5 minutes at room temperature. And (3) mixing the two groups of premixed solutions with the group C premixed solution in equal volume respectively to obtain about 500 mu L of transfection reagent (small RNA mixed solution), blowing and uniformly mixing, incubating at room temperature for 20 minutes, adding 500 mu L of the prepared transfection reagent into each hole, incubating in an incubator at 37 ℃ for 6 hours, changing to a normal 10% FBS DMEM/F12 culture medium, continuing culturing for 18-48 hours, and observing the result.
(2) Cytokine assay
The transfected cells were cultured for 48 hours, and the culture broth was collected and sent to the institute of biotechnology in northern Beijing to determine the estradiol content.
According to measurement, miR-615-5p promotes the secretion of estrogen of human primary granulosa cells and KGN cell lines (figure 4 and figure 5).
Example 3 decreased expression of miR-615-5p in the ovary of polycystic ovary syndrome model mouse
In vivo experiments: 10 female mice with a gestational period of 16 days were randomly divided into two groups.
The control group was subcutaneously injected with 200ul of sesame oil per day, and the experimental group was subcutaneously injected with 200ul of sesame oil containing DHT (dihydrotestosterone) (wherein the amount of DHT was 250ug) per day for 3 days. Collecting ovaries of offspring adult female mice, making paraffin sections, HE staining, and observing the ovary structure. And simultaneously extracting RNA of the ovary, and detecting the expression condition of miR-615-5 p.
Adult C57 female mice and male mice are combined in a ratio of 2:1 at 4 pm in the first 1 day, the emboli are picked up in the morning of the next day, and female mice with emboli are marked and divided into two groups, which is marked as day 1. The control mice were injected with 200ul of sesame oil subcutaneously into the back of each day 16, 17, and 18 days after the treatment of thrombosis, and the experimental mice were injected with 200ul of sesame oil containing DHT (dihydrotestosterone) (wherein the amount of DHT was 250ug) subcutaneously into the back of each day for 3 days. After 2 months, ovaries of offspring female mice were collected, fixed with 4% paraformaldehyde for 48 hours, washed with running water for 6 hours, embedded, HE-stained, and observed under a microscope for ovarian structure.
The results showed that the ovaries of offspring adult female mice in the DHT-treated group exhibited a polycystic shape compared to the control group (fig. 6).
The embedding steps are as follows:
70% ethanol 15 min-80% ethanol 15 min-90% ethanol 15 min-95% ethanol 15 min-absolute ethanol 115 min-absolute ethanol 215 min-ethanol/xylene (1:1)7 min-xylene 16 min-xylene 26 min-paraffin 118 min-paraffin 218 min-paraffin 318 min.
The absolute ethyl alcohol 1 is soaked in a first absolute ethyl alcohol plate for 15 minutes, and then taken out and placed in a second absolute ethyl alcohol plate to be soaked for 15 minutes. Xylene and paraffin are similar.
HE staining procedure was as follows:
xylene 115min- - -xylene 215 min- - -alcohol/xylene (1:1)5min- - -absolute ethyl alcohol 15min- - -absolute ethyl alcohol 25min- - -95% ethyl alcohol 5min- - -80% ethyl alcohol 5min- - -70% ethyl alcohol 5min- - -hematoxylin 12min- - -distilled water washing 2min- - -hydrochloric acid alcohol 10s- - -distilled water washing 2min- - -70% ethyl alcohol 3min- - -80% ethyl alcohol 3min- - -eosin 60s- - -90% ethyl alcohol 3min- - -95% ethyl alcohol 3min- - -absolute ethyl alcohol 13 min- - -absolute ethyl alcohol 23 min- - -alcohol/xylene (1:1)3min- - -xylene 13 min- - -xylene 23 min- - -xylene -a cover sheet.
Extracting total RNA of the ovary, and detecting the expression condition of miR-615-5 p.
The result shows that the expression level of miR-615-5p in the ovary of a polycystic ovary syndrome model mouse is remarkably reduced (figure 7).
Although the invention has been described in detail hereinabove with respect to a general description and specific embodiments thereof, it will be apparent to those skilled in the art that modifications or improvements may be made thereto based on the invention. Accordingly, such modifications and improvements are intended to be within the scope of the invention as claimed.
Sequence listing
<110> eastern plum
Li Xiangdong
<120> use of biomarker for diagnosis
<160> 5
<170> SIPOSequenceListing 1.0
<210> 1
<211> 22
<212> RNA
<213> Artificial Sequence (Artificial Sequence)
<400> 1
gggggucccc ggugcucgga uc 22
<210> 2
<211> 47
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 2
gtcgtatcca gtgcagggtc cgaggtgcac tggatacgac catccga 47
<210> 3
<211> 23
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 3
tgcacggggg tccccggtgc tcg 23
<210> 4
<211> 21
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 4
ctcaactggt gtcgtggagt c 21
<210> 5
<211> 22
<212> RNA
<213> Artificial Sequence (Artificial Sequence)
<400> 5
gggggucccc ggugcucgga uc 22

Claims (6)

1. The miRNA biomarker for diagnosis of polycystic ovarian syndrome is miR-615-5 p.
2. The use of the miRNA biomarker of claim 1 in the preparation or screening of medicaments for diagnosis and treatment of human polycystic ovarian syndrome.
3. Use of the miRNA biomarker of claim 1 in preparation of a human polycystic ovary syndrome detection reagent.
4. The use according to claim 3, wherein the detection reagent is selected from reagents related to the detection of the biomarker miR-615-5p by southern blotting, northern blotting, PCR, reverse transcriptase PCR, real-time quantitative PCR, nano-array, macro-array, autoradiography or in situ hybridization.
5. The kit for diagnosing the polycystic ovarian syndrome is characterized by comprising one or more primers and/or probes for specifically detecting the expression level of miR-615-5 p.
6. The kit according to claim 5, wherein the kit comprises primers for detecting miR-615-5p by using a real-time quantitative PCR method, and the sequences of the primers are as follows: miR-615-5p-RT 5'-GTCGTATCCAGTGCAGGGTCCGAGGTGCACTGGATACGACCATCCGA-3'
miR-615-5p-F:5′- TGCACGGGGGTCCCCGGTGCTCG -3′
miR-615-5p-R:5′- CTCAACTGGTGTCGTGGAGTC -3′。
CN202010989515.4A 2020-09-18 2020-09-18 Application of biomarker for diagnosis Withdrawn CN112342288A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010989515.4A CN112342288A (en) 2020-09-18 2020-09-18 Application of biomarker for diagnosis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010989515.4A CN112342288A (en) 2020-09-18 2020-09-18 Application of biomarker for diagnosis

Publications (1)

Publication Number Publication Date
CN112342288A true CN112342288A (en) 2021-02-09

Family

ID=74357334

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010989515.4A Withdrawn CN112342288A (en) 2020-09-18 2020-09-18 Application of biomarker for diagnosis

Country Status (1)

Country Link
CN (1) CN112342288A (en)

Similar Documents

Publication Publication Date Title
Chen et al. The role of MiRNA in polycystic ovary syndrome (PCOS)
Mu et al. Non-coding RNAs in polycystic ovary syndrome: a systematic review and meta-analysis
Roth et al. Altered microRNA and gene expression in the follicular fluid of women with polycystic ovary syndrome
Xu et al. Differentially expressed micoRNAs in human oocytes
Tochigi et al. Loss of miR-542-3p enhances IGFBP-1 expression in decidualizing human endometrial stromal cells
Karakaya et al. Poor ovarian response in women undergoing in vitro fertilization is associated with altered microRNA expression in cumulus cells
Naji et al. Expression of miR-15a, miR-145, and miR-182 in granulosa-lutein cells, follicular fluid, and serum of women with polycystic ovary syndrome (PCOS)
He et al. H19 regulates trophoblastic spheroid adhesion by competitively binding to let-7
Deswal et al. Dissecting the role of micro-RNAs as a diagnostic marker for polycystic ovary syndrome: a systematic review and meta-analysis
Hong et al. Down-regulation of miR-378a-3p induces decidual cell apoptosis: a possible mechanism for early pregnancy loss
Luo et al. The role of miRNAs in polycystic ovary syndrome with insulin resistance
Chen et al. A novel platform for discovery of differentially expressed microRNAs in patients with repeated implantation failure
US20200270690A1 (en) Serum/plasma LncRNA marker composition associated with auxiliary diagnosis of intrahepatic cholestasis of pregnancy and application thereof
Tang et al. Expression profile of micro-RNAs and functional annotation analysis of their targets in human chorionic villi from early recurrent miscarriage
Song et al. miRNA-592 is downregulated and may target LHCGR in polycystic ovary syndrome patients
CN112639131A (en) Biomarkers for diagnosing or predicting ovarian responsiveness to follicle stimulating hormone and uses thereof
CN107674916B (en) Application of circular RNA in colorectal cancer biomarker
CN112662752B (en) Application of biomarker for diagnosis
García-Padilla et al. Differential chamber-specific expression and regulation of long non-coding RNAs during cardiac development
Yang et al. Lnc-AL445665. 1–4 may be involved in the development of multiple uterine leiomyoma through interacting with miR-146b-5p
CN112852946A (en) Diagnostic biomarker and application thereof
CN112430665B (en) Molecular biomarker for diagnosing and treating triple negative breast cancer and application thereof
McAllan et al. Integrative genomic analyses in adipocytes implicate DNA methylation in human obesity and diabetes
CN112342288A (en) Application of biomarker for diagnosis
Pheiffer et al. Screening for gestational diabetes mellitus: the potential of microRNAs

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
WW01 Invention patent application withdrawn after publication
WW01 Invention patent application withdrawn after publication

Application publication date: 20210209